Aquestive Therapeutics Inc (NASDAQ: AQST) kicked off on Friday, up 5.77% from the previous trading day, before settling in for the closing price of $4.68. Over the past 52 weeks, AQST has traded in a range of $1.25-$6.23.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -4.81%. While this was happening, its average annual earnings per share was recorded -225.00%. With a float of $79.37 million, this company’s outstanding shares have now reached $91.06 million.
Let’s determine the extent of company efficiency that accounts for 135 employees.
Aquestive Therapeutics Inc (AQST) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Aquestive Therapeutics Inc is 12.84%, while institutional ownership is 39.55%. The most recent insider transaction that took place on Mar 15 ’24, was worth 300,000. In this transaction Chief Innovation/Tech Officer of this company sold 50,000 shares at a rate of $6.00, taking the stock ownership to the 984,476 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Chief Innovation/Tech Officer sold 25,000 for $5.19, making the entire transaction worth $129,685. This insider now owns 1,040,371 shares in total.
Aquestive Therapeutics Inc (AQST) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -225.00% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Take a look at Aquestive Therapeutics Inc’s (AQST) current performance indicators. Last quarter, stock had a quick ratio of 6.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.35, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Looking closely at Aquestive Therapeutics Inc (NASDAQ: AQST), its last 5-days average volume was 1.44 million, which is a drop from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 39.52%. Additionally, its Average True Range was 0.31.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 88.85%, which indicates a significant increase from 54.95% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.05% in the past 14 days, which was lower than the 70.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.35, while its 200-day Moving Average is $3.49. However, in the short run, Aquestive Therapeutics Inc’s stock first resistance to watch stands at $5.04. Second resistance stands at $5.14. The third major resistance level sits at $5.31. If the price goes on to break the first support level at $4.77, it is likely to go to the next support level at $4.60. Should the price break the second support level, the third support level stands at $4.50.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
The company with the Market Capitalisation of 450.75 million has total of 91,039K Shares Outstanding. Its annual sales at the moment are 50,580 K in contrast with the sum of -7,870 K annual income. Company’s last quarter sales were recorded 20,100 K and last quarter income was -2,750 K.
